Evidence map›Paper›PMID 22052903›Full record

ArticleThe Journal of biological chemistry2012

Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.

Wenbin Hu, Fang Wang, Jingsheng Tang, Xinyu Liu, Zhu Yuan, Chunlai Nie, Yuquan Wei

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenbin HuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China.
Fang WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China.
Jingsheng TangChongQing NewFine Biology Technology Co., Ltd., 8 Lingfang Road, Banqiao District, Chongqing 402460, China.
Xinyu LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China.
Zhu YuanState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China.
Chunlai NieState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China. Electronic address: niecl1022@hotmail.com.
Yuquan WeiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 4 Keyuan Road, Hitech District, Chengdu 610041, China.
Sichuan University · CNState Key Laboratory of Biotherapy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance of ovarian cancer has been previously attributed to the expression and activation of Bcl-2 family proteins. BH3-mimetic molecules possessing potential anticancer activity are able to inhibit antiapoptotic Bcl-2 family proteins. AT101 (R-(-)-gossypol), a natural BH3-mimetic molecule, has shown anti-tumor activity as a single agent and in combination with standard anticancer therapies in a variety of tumor models. Here, we report the effect of AT101 on apoptosis in cisplatin-resistant ovarian cancer cells and identify the major molecular events that determine sensitivity. AT101 induced cell apoptosis by activating Bax through a conformational change, translocation, and oligomerization. The inhibition of Bax expression only partially prevented caspase-3 cleavage. However, the gene silencing of Bax had no effect on mitochondrial Smac release. Further experiments demonstrated that Smac reduction inhibited caspase-3 activation and attenuated cell apoptosis. More importantly, the inhibition of Smac or overexpression of XIAP attenuated Bax activation in ovarian cells. Furthermore, our data indicate that the Akt-p53 pathway is involved in the regulation of Smac release. Taken together, our data demonstrate the role of Smac and the molecular mechanisms of AT101-induced apoptosis of chemoresistant ovarian cancer cells. Our findings suggest that AT101 not only triggers Bax activation but also induces mitochondrial Smac release. Activated Smac can enhance Bax-mediated cellular apoptosis. Therefore, Smac mediates Bax activation to determine the threshold for overcoming cisplatin resistance in ovarian cancer cells.

Indexed as

Antineoplastic AgentsApoptosisApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCaspase 3Cell Line, TumorCisplatinDown-RegulationDrug Resistance, NeoplasmFemaleGossypolHumansIntracellular Signaling Peptides and ProteinsMitochondriaMitochondrial ProteinsOvarian NeoplasmsAntineoplastic AgentsApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCaspase 3CisplatinDIABLO protein, humanGossypolgossypol acetic acidIntracellular Signaling Peptides and ProteinsMitochondrial ProteinsProto-Oncogene Proteins c-aktTumor Suppressor Protein p53X-Linked Inhibitor of Apoptosis Protein

Identifiers

PMID22052903
PMCPMC3249122
OpenAlexW2052998306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.